VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
COLL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
COLLCollegium Pharmaceutical, Inc.
$25.55$841M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. COLL
  4. Financial Ratios

Collegium Pharmaceutical, Inc. (COLL) Financial Ratios

Latest Ratios: P/E Ratio 26.6x · EV/EBITDA 5.1x · ROE 23.7%. (2013–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

COLL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$841M$1.8B$1.2B$1.3B$785M$767M$704M$688M$566M$559M$378M
Enterprise Value$1.5B$2.5B$1.9B$1.7B$1.3B$839M$797M$540M$431M$441M$229M
P/E Ratio →26.5726.7615.4023.86—10.0426.36————
P/S Ratio1.032.351.832.271.692.772.272.322.0219.62220.79
P/B Ratio3.416.095.066.584.033.783.787.876.185.372.80
P/FCF2.505.615.704.696.407.55—32.253.90——
P/OCF2.555.585.654.686.327.407.4924.783.34——

P/E links to full P/E history page with 30-year chart

COLL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—3.243.083.042.853.032.571.821.5415.50133.66
EV / EBITDA5.076.125.745.447.669.706.76—4.77——
EV / EBIT8.1814.4511.2810.8238.4247.5714.11————
EV / FCF—7.729.586.2810.778.26—25.302.97——

COLL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin59.3%59.3%59.8%57.5%45.2%54.4%58.0%34.7%40.9%90.9%87.6%
Operating Margin24.0%24.0%26.9%29.5%7.2%6.4%18.1%-8.0%-7.4%-264.9%-5498.7%
Net Profit Margin8.1%8.1%11.0%8.5%-5.4%25.8%8.6%-7.7%-14.0%-262.9%-5504.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE23.7%23.7%32.6%24.7%-12.6%36.8%19.6%-25.4%-40.0%-62.7%-85.6%
ROA3.8%3.8%4.9%4.2%-2.7%10.7%5.6%-7.6%-18.3%-50.3%-72.5%
ROIC14.0%14.0%15.5%18.4%5.0%4.8%38.8%————
ROCE15.8%15.8%18.5%23.4%5.8%4.3%22.1%-22.8%-19.9%-62.1%-81.4%

COLL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity3.123.123.753.453.641.281.430.250.130.010.03
Debt / EBITDA2.282.282.532.134.122.992.26—0.13——
Net Debt / Equity—2.293.452.232.750.360.50-1.70-1.48-1.13-1.11
Net Debt / EBITDA1.671.672.331.383.110.840.79—-1.50——
Debt / FCF—2.103.881.594.370.71—-6.95-0.93——
Interest Coverage2.132.132.331.910.540.841.95-24.00-0.94—-1000.87

COLL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.571.570.951.170.971.131.161.271.274.246.92
Quick Ratio1.481.480.881.100.861.071.101.221.234.186.86
Cash Ratio0.920.920.320.680.400.670.730.840.783.776.68
Asset Turnover—0.470.380.500.400.400.480.970.960.210.01
Inventory Turnover7.767.767.157.445.477.268.3420.0821.191.430.16
Days Sales Outstanding—98.82132.10115.61144.07139.5498.1089.75101.46127.78454.17

COLL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield——————————6.5%
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.8%3.7%6.5%4.2%—10.0%3.8%————
FCF Yield40.0%17.8%17.6%21.3%15.6%13.3%—3.1%25.6%——
Buyback Yield3.0%1.4%5.2%5.8%1.8%6.2%0.0%0.1%0.1%0.0%0.0%
Total Shareholder Yield3.0%1.4%5.2%5.8%1.8%6.2%0.0%0.1%0.1%0.0%6.5%
Shares Outstanding—$40M$40M$42M$34M$41M$35M$33M$33M$30M$24M

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetStrained
Cash FlowStable
Top Statement Risk

Leverage Limits Shortfall Tolerance

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Low Headline Multiples Mask Leverage

Based on reported figures, COLL trades at a 24.81 trailing P/E and 4.88 EV/EBITDA, yet a 3.25 forward P/E implies sharp expected earnings recovery that depends on margins returning to prior levels.

The gap between the trailing P/E of 24.81 and the forward P/E of 3.25 suggests the market is pricing in a substantial earnings rebound rather than the current quarterly run-rate, which warrants scrutiny given the recent EPS miss and net margin of 8.1%. The EV/EBITDA of 4.88 is undemanding relative to specialty pharma peers such as Supernus at 5.46 and Harmony at 5.74, but the enterprise value includes roughly $1.1B of debt, so equity holders bear most of the leverage risk. Investors should monitor whether forward estimates are realized before treating the low multiples as evidence of mispricing.

Operating Margin Recovery Remains Fragile

According to reported quarterly figures, COLL's operating margin rebounded to 11.9% in 2026Q3 from 1.9% in 2026Q2, yet remains well below the 30.4% peak reported in 2025Q3.

The swing from a 1.9% operating margin to 11.9% in consecutive quarters suggests that SG&A discipline and gross margin recovery to 58.0% are driving earnings, but the trajectory is volatile rather than structurally stable. Compared with its own 2025 history, current profitability is roughly 18 percentage points weaker at the operating line, which may indicate that prior peak margins reflected favorable accrual timing. Earnings quality appears sensitive to rebate and return accruals, and further analysis of those components is warranted before extrapolating recent recovery.

Debt Service Comfort Deteriorating Sharply

Based on the reported figures, COLL's debt-to-equity ratio rose to 3.67 in 2026Q3 while interest coverage fell to 1.36, down from 3.00 in 2025Q3, suggesting narrowing debt service headroom.

Compared with its own history, the debt-to-EBITDA ratio expanded from 7.79 to 36.42 over the past year, which appears driven by compressed quarterly EBITDA rather than new borrowing alone. An interest coverage ratio near 1.4 leaves little room for earnings shortfalls before debt service becomes strained, a concern amplified by the roughly $1.1B debt load relative to equity of about $296M. Refinancing and covenant terms are not disclosed in the provided data, so the degree of near-term risk cannot be fully assessed from these figures.

Thin Current Buffer Against Obligations

As reported in financial statements, COLL's current ratio declined to 1.01 and quick ratio to 0.87 in 2026Q3, down from 1.71 and 1.62 in 2026Q1, leaving a narrow cushion against near-term liabilities.

A quick ratio below 1.0 means the company relies on cash generation and receivable collection rather than liquid assets alone to meet current obligations, which becomes a concern given cash of $144.8M against roughly $1.1B of debt. The cash conversion cycle of 219 days, driven by a DIO of 127 and DSO of 102, suggests working capital is absorbing significant capital and may tie up liquidity. Under a severe stress scenario involving a revenue shock or tightened opioid production quotas, this liquidity position would likely require reliance on operating cash flow, which the provided data does not guarantee.

Cash Generation Overstates Financial Flexibility

Based on reported figures, COLL's cumulative operating cash flow of roughly $636M over ten quarters appears strong, yet a 3.67 debt-to-equity ratio suggests cash generation may overstate true financial flexibility.

The most commonly misapplied metric for a specialty pharma company with heavy amortization is EV/EBITDA or free cash flow yield, which can flatter a leveraged business by excluding the cost of acquired intangibles and debt service obligations. Using FCF margin alone obscures that quarterly figures swing from -5.8% to 59.6% largely on working capital timing. A more appropriate lens would be net debt to normalized free cash flow after amortization and rebate accrual adjustments, which would better reflect the capacity to service roughly $1.1B of debt.

Download Financial Ratios Data

Includes 30+ ratios · 13 years · Updated daily

Consensus & Technical Research Suite
Open COLL Terminal

COLL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

COLL — Frequently Asked Questions

Quick answers to the most common questions about buying COLL stock.

What is Collegium Pharmaceutical, Inc.'s P/E ratio?

Collegium Pharmaceutical, Inc.'s current P/E ratio is 26.6x. The historical average is 20.5x. This places it at the 80th percentile of its historical range.

What is Collegium Pharmaceutical, Inc.'s EV/EBITDA?

Collegium Pharmaceutical, Inc.'s current EV/EBITDA is 5.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.6x.

What is Collegium Pharmaceutical, Inc.'s ROE?

Collegium Pharmaceutical, Inc.'s return on equity (ROE) is 23.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -37.8%.

Is COLL stock overvalued?

Based on historical data, Collegium Pharmaceutical, Inc. is trading at a P/E of 26.6x. This is at the 80th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Collegium Pharmaceutical, Inc.'s profit margins?

Collegium Pharmaceutical, Inc. has 59.3% gross margin and 24.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Collegium Pharmaceutical, Inc. have?

Collegium Pharmaceutical, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.